US. Serial No. 16/908,426
`Response to Non-Final Office Action mailed January 24, 2022
`
`Attorney Docket No. 46682-701.317
`
`AMENDMENTS TO THE CLAIMS
`
`This listing of claims replaces all prior versions and listing of claims in the above-
`
`referenced patent application. The following amendments do not constitute an admission
`
`regarding the patentability of the amended subject matter and should not be so construed,
`
`Amendments to the claims were made for purposes of more clearlystating the claimed subject
`
`matter and do not add newmatteror alter the scope of the claims. Deletions are denoted by
`
`lstr-etheouek| and additions are denoted by underline.
`
`Listing of the Claims
`
`1.-30. (Canceled).
`
`31. (Currently Amended) A kit comprising:
`
`a. a container comprising a monotherapeutic pharrnaceutical composition, the
`
`monotherapeutic pharmaceutical composition comprising:
`
`i,
`
`oneand-ae-merethar-one-asole ophthalmic agent, wherein the soleophthalmic
`
`agent is atropine or atropine sulfate, and wherein the atropine or atropine sulfate is
`
`providedat about 0.01 mg/g to about 0.5 mg/g:
`
`i. water;
`
`it. a buffer to provide a pHfrom about 4.8 to about 6.4;
`
`iv. a tonicity adjusting agent; and
`
`Vv. aviscosity agent: and
`
`b. instructions for use.
`
`32. (Currently Amended} The kit of claim 31, wherein the atropine or atropine sulfate is
`
`present in the monotherapeutic pharmaceutical composition at a concentration of from about
`
`0.01 me/g to about 0.3 me/gor from about 0.1 me/g to about 0.2 mg/g.
`
`33. (Currently Amended) The kit of claim 31, wherein the atropine or atropine sulfate is
`
`presentin the monotherapeutic pharmaceutical composition at a concentration of about 0.1 me/g,
`
`about 0.2 mg/g, about 0.25 mg/g, about 0.3 mg/g, about 0.4 mg/g, or about 0.5 mg/g.
`
`34. (Previously Presented} The kit of claim 31, wherein the buffer comprises a borate, a
`
`borate-polyol complex, a phosphate buffering agent, a citrate buffering agent, an acetate
`
`
`
`US. Serial No. 16/908,426
`Response to Non-Final Office Action mailed January 24, 2022
`
`Attorney Docket No. 46682-701.317
`
`buffering agent, a carbonate buffering agent, an organic buffering agent, an amino acid buffering
`
`agent, ora combination thereof,
`
`35. (Previously Presented) The kit of claim 31, wherein the buffer comprises sodium
`
`dihydrogen phosphate, disodium hydrogen phosphate, or a combination thereof,
`
`36. (Canceled).
`
`37. (Previously Presented) The kit of clairn 31, wherein the tonicity adjusting agent
`
`comprises a halide salt of a monovalent cation,
`
`38. (Canceled),
`
`39. (Previously Presented) The kit of claim 31, wherein the viscosity agent comprises
`
`hydroxyethyl cellulose, hydroxypropyl cellulose, or hydroxypropyimethyl-cellulose (HPMC).
`
`40. (Carrently Amended} The kitof claim 31, wherein the monotherapeutic
`
`pharmaceutical composition is substantially free of a preservative.
`
`41. (Currently Amended) The kit of claim 31, wherein the monotherapeutic
`
`pharmaceutical composition comprises less than about 1%ofa preservative.
`
`42. (Carrently Amended} The kitof claim 31, wherein the monotherapeutic
`
`pharmaceutical composition further coniprises a preservative.
`
`43. (Previously Presented) The kit of claim 42, wherein a concentration of the
`
`preservative is from about 0.000 1%to about 1%.
`
`44. (Previously Presented) The kit of claim 42, wherein the preservative is selected from
`
`benzalkonium chloride, cetrimonium, sodium perborate, stabilized oxychloro cornplex,
`
`poly quaternium-1, chlorobutanol, edetate disodium, polyhexamethylene biguanide, or
`
`combinations thereof.
`
`45. (Currently Amended) The kit of claim 31, wherein the monotherapeutic
`
`pharmaceutical composition is essentially free of procaine and benacty ane, or pharmaceutically
`
`acceptable salts thereof,
`
`46.-48. (Canceled).
`
`49. (Currently Amended) The kit of claim 31, wherein the monotherapeutic
`
`pharmaceutical compositionis a solution.
`
`30. (Currently Amended) The kit of claim 31, wherein the monotherapeutic
`
`pharmaceutical compasition is sterile.
`
`
`
`US. Serial No. 16/908,426
`Response to Non-Final Office Action mailed January 24, 2022
`
`Attorney Docket No. 46682-701.317
`
`St. (Currently Amended} The kit of claim 31, wherein the monotherapeutic
`
`pharmaceutical composition further comiprises a stabilizing agent.
`
`52. (Previously Presented) The kit of claim 51, wherein the stabilizing agentis selected
`
`from the group consisting of glycerol, methionine, monothioglycerol, ethylenediaminetetraacetic
`
`acid (EDTA), ascorbic acid, polysorbate 80, polysorbate 20, arginine, heparin, dextran sulfate,
`
`cyclodextrins, pentosan polysulfate, magnesium, zinc, and combinations thereof.
`
`53. (Previously Presented) The kit of claim 52, wherein the stabilizing agent is EDTA,
`
`
